Clinical Trials in Jingzhou, Hubei
24 recruiting
Showing 1–20 of 23 trials
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Non-small Cell Lung Cancer
Summit Therapeutics1,600 enrolled253 locationsNCT05899608
Recruiting
Phase 2Phase 3
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.344 enrolled30 locationsNCT07378527
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled186 locationsNCT07100080
Recruiting
Phase 1Phase 2
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Advanced Lung Cancer
BioNTech SE594 enrolled58 locationsNCT06892548
Recruiting
Phase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.135 enrolled16 locationsNCT07236099
Recruiting
Phase 2
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.134 enrolled32 locationsNCT06897579
Recruiting
Not Applicable
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
HypothermiaCancer SurgeryDelirium+1 more
Peking University First Hospital3,992 enrolled36 locationsNCT06256354
Recruiting
Phase 3
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
Akeso560 enrolled53 locationsNCT07010263
Recruiting
Phase 3
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.383 enrolled46 locationsNCT06842199
Recruiting
Phase 3
A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
Plaque Psoriasis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.537 enrolled55 locationsNCT07357831
Recruiting
Not Applicable
Thumbtack Needle in the Treatment of NVP
Nausea and Vomiting in Pregnancy (NVP)
Dongmei Huang320 enrolled13 locationsNCT06566274
Recruiting
Phase 3
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
Allergic RhinitisAllergic Rhinoconjunctivitis
ALK-Abelló A/S300 enrolled30 locationsNCT07060885
Recruiting
Phase 1Phase 2
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.252 enrolled43 locationsNCT06459973
Recruiting
Phase 3
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.246 enrolled60 locationsNCT07107256
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 4
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
CKD (Chronic Kidney Disease) Stage 5D
Guangdong Provincial People's Hospital9,000 enrolled139 locationsNCT04381143
Recruiting
Phase 3
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Beijing InnoCare Pharma Tech Co., Ltd.552 enrolled62 locationsNCT06775860
Recruiting
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
Cognitive Dysfunction
Tongji Hospital5,000 enrolled21 locationsNCT07128186
Recruiting
Phase 2Phase 3
ICP-332 in Subjects With Non-segmental Vitiligo
Non-segmental Vitiligo
Beijing InnoCare Pharma Tech Co., Ltd.603 enrolled45 locationsNCT07047612